- Home
- EHI vs APLT Comparison
EHI vs APLT Comparison
Compare EHI & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- APLT
- Stock Information
- Founded
- EHI 2003
- APLT 2016
- Country
- EHI United States
- APLT United States
- Employees
- EHI N/A
- APLT N/A
- Industry
- EHI Investment Managers
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- EHI Finance
- APLT Health Care
- Exchange
- EHI Nasdaq
- APLT Nasdaq
- Market Cap
- EHI 192.4M
- APLT 178.6M
- IPO Year
- EHI N/A
- APLT 2019
- Fundamental
- Price
- EHI $6.39
- APLT $0.93
- Analyst Decision
- EHI
- APLT Buy
- Analyst Count
- EHI 0
- APLT 5
- Target Price
- EHI N/A
- APLT $4.13
- AVG Volume (30 Days)
- EHI 44.5K
- APLT 2.4M
- Earning Date
- EHI 01-01-0001
- APLT 11-10-2025
- Dividend Yield
- EHI 11.54%
- APLT N/A
- EPS Growth
- EHI N/A
- APLT N/A
- EPS
- EHI N/A
- APLT N/A
- Revenue
- EHI N/A
- APLT $121,000.00
- Revenue This Year
- EHI N/A
- APLT N/A
- Revenue Next Year
- EHI N/A
- APLT $5,935.35
- P/E Ratio
- EHI N/A
- APLT N/A
- Revenue Growth
- EHI N/A
- APLT N/A
- 52 Week Low
- EHI $6.00
- APLT $0.30
- 52 Week High
- EHI $7.75
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- EHI 43.05
- APLT 46.05
- Support Level
- EHI $6.32
- APLT $0.75
- Resistance Level
- EHI $6.40
- APLT $0.95
- Average True Range (ATR)
- EHI 0.04
- APLT 0.13
- MACD
- EHI 0.01
- APLT -0.06
- Stochastic Oscillator
- EHI 55.24
- APLT 30.60
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.